PTEN and BRCA1 tumor suppressor loss associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in a murine model of ovarian cancer
N. Shakfa, D. Li, G. Conseil, E. D. Lightbody, J. Wilson-Sanchez, A. Hamade, S. Chenard, B. J. Laight, A. Asante, K. Tyryshkin, M. Köbel, M. Koti
This study examines how PTEN and BRCA1 loss in ovarian cancer affects tumor immune microenvironment response to STING pathway activation, showing improved survival in PTEN-deficient tumors with STING therapy.
bioRxiv · Jun 27, 2022 · PreprintImmunology